UNSPSC 51291903: Nitracrine

This classification denotes an intercalating agent with the molecular formula C18H20N4O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 712MLZ30SB, chemically known as 1,3-propanediamine, n,n-dimethyl-n-(1-nitro-9-acridinyl)-, dihydrochloride but generally known as nitracrine, which bears US NIH Compound Identifier 20628. European Medicines Agency schedules Nitracrine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09314MIG.

UNSPSC 51291903 Nitracrine is a Commodity code that encompasses pharmaceutical products and drug-related systems procured by state and local health agencies, public health departments, and cooperative purchasing alliances to support community health, emergency response, and medication management initiatives. Recent state and local solicitations under this code show demand for naloxone (opioid overdose reversal medication), safe drug deactivation systems, generic multi-source pharmaceuticals, and over-the-counter products distributed through established pharmaceutical supply chains and authorized wholesale networks. Issuing bodies include county health departments, state health and human services agencies, and regional cooperative purchasing organizations that aggregate demand across multiple jurisdictions. The work involves procuring finished pharmaceutical products and medical supplies on a recurring annual or multi-year basis, with vendors managing supply chain logistics, compliance with federal drug regulations and manufacturing standards, and delivery to designated public health facilities.

Recent activity spans Florida, Texas, Minnesota, and Oregon. Seminole County, Florida posted IFB 60459723LAS in June 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building, with a response deadline of July 26, 2023 (note: date discrepancy in source). The Texas Health and Human Services Commission issued RFI HHS0017013 in April 2026 to explore vendor capabilities for a direct-to-manufacturer prescription program outside traditional pharmacy benefit manager channels. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, released RFP S1070000015802 in January 2026 for generic multi-source pharmaceuticals and OTC products to be distributed through AmerisourceBergen Drug Corporation, Cardinal Health, and Morris & Dickson Co., with responses due March 26, 2026 and contract effectiveness July 1, 2026. Vendors must comply with current Good Manufacturing Practices, the Drug Supply Chain Security Act, and maintain substantial insurance coverage including commercial general liability of $5 million or higher per occurrence.